Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna’s combo jab; clinical trial recover from pandemic; and Astellas’s US commercial head speaks. 

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 June 2024, including: Boehringer Ingelheim GmbH best in MASH?; biopharma funding on an upswing?; Moderna, Inc.’s combo jab; clinical trial recover from pandemic; and Astellas Pharma, Inc.’s US commercial head speaks. 

This and all our other podcasts are available on the Citeline channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data" - Scrip, 7 June, 2024.)

(Also see "Financial Market At The Start Of An Upswing, For Companies With Focused Strategies" - Scrip, 13 June, 2024.)

(Also see "Moderna Pips Pfizer/BioNTech In Combo Jab Race" - Scrip, 10 June, 2024.)

(Also see "What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet" - Scrip, 12 June, 2024.)

(Also see "Astellas’s US Commercial Head Petroutsas On New Launches" - Scrip, 11 June, 2024.)

Citeline · Scrip's Five Must-Know Things - 17 June 2024

Open Media

More from Financing

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By 

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.